INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 23, 2012 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Other acquisition or disposition | -- | -- | 1,532 |
| Feb 23, 2012 |
Director
Trans History: 368
|
Director | Form 4 | Conversion of derivative security | 10,000 | -- | 10,000 |
| Feb 23, 2012 |
Director
Trans History: 368
|
Director | Form 4 | Conversion of derivative security | 10,000 | -- | 10,000 |
| Feb 23, 2012 |
Director
Trans History: 368
|
Director | Form 4 | Conversion of derivative security | 10,000 | -- | 10,000 |
| Feb 23, 2012 |
Director
Trans History: 368
|
Director | Form 4 | Conversion of derivative security | 10,000 | -- | 10,000 |
| Feb 21, 2012 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 49,428 | -- | -- |
| Feb 21, 2012 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 15,000 | -- | 30,000 |
| Feb 21, 2012 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 20,000 | -- | -- |
| Feb 21, 2012 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,438 | -- | -- |
| Feb 16, 2012 |
VP Controller and Asst Treasur
Trans History: 372
|
VP Controller and Asst Treasur | Form 4 | Other acquisition or disposition | -- | -- | 4,264 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.